Celecoxib

Pre-clinicalTerminated

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Familial Adenomatous Polyposis (FAP)

Conditions

Familial Adenomatous Polyposis (FAP)

Trial Timeline

Nov 1, 2004 → Nov 1, 2008

NCT ID

NCT00151476

About Celecoxib

Celecoxib is a pre-clinical stage product being developed by Pfizer for Familial Adenomatous Polyposis (FAP). The current trial status is terminated. This product is registered under clinical trial identifier NCT00151476. Target conditions include Familial Adenomatous Polyposis (FAP).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00976716	Phase 3	Completed	Sep 1, 2009	Nov 1, 2009	Pain
NCT00585156	Phase 1	Terminated	Jun 1, 2008	Sep 1, 2008	Bone Ingrowth
NCT00474773	Pre-clinical	Completed	Jun 1, 2007	Dec 1, 2009	Pain Management
NCT00304317	Approved	Withdrawn	Mar 1, 2006	Aug 1, 2008	Ureteral Calculi
NCT00296127	Phase 1	Completed	Feb 1, 2006	Mar 1, 2006	Healthy Volunteers
NCT00151476	Pre-clinical	Terminated	Nov 1, 2004	Nov 1, 2008	Familial Adenomatous Polyposis (FAP)
NCT00163241	Phase 3	Terminated	Jun 1, 2004	Jan 1, 2006	Osteoarthritis
NCT00194090	Approved	Completed	Jun 1, 2004	Sep 1, 2005	Knee Osteoarthritis
NCT00633438	Approved	Completed	Jan 1, 2004	Jun 1, 2004	Arthroscopy
NCT00638807	Approved	Completed	Dec 1, 2003	Jul 1, 2004	Osteoarthritis, Knee
NCT00181532	Phase 2	Completed	May 1, 2003	Jan 1, 2008	Non Small Cell Lung Carcinoma
NCT00633386	Approved	Completed	Feb 1, 2003	Aug 1, 2003	Arthroscopy
NCT00136487	Phase 2/3	Completed	Oct 1, 2002	Sep 1, 2006	Prostate Cancer
NCT00141193	Phase 3	Completed	Feb 1, 2001	May 1, 2007	Colorectal Adenoma
NCT00036283	Phase 2	Completed	Nov 1, 2000	Apr 1, 2004	Precancerous Conditions

Competing Products

20 competing products in Familial Adenomatous Polyposis (FAP)

See all competitors

Product	Company	Stage	Hype Score
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	40
SHR-1209	Jiangsu Hengrui Medicine	Phase 2	52
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo	Jiangsu Hengrui Medicine	Phase 3	77
Rosuvastatin 20mg + Placebo	AstraZeneca	Phase 3	77
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium	AstraZeneca	Phase 3	77
Rosuvastatin + Placebo	AstraZeneca	Phase 3	77
Rosuvastatin 20mg	AstraZeneca	Phase 3	77
AZD0780 + Placebo	AstraZeneca	Phase 3	77
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	77
Statins and Ezetimibe	Merck	Pre-clinical	23
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo	Merck	Phase 3	77
MK-0524A + MK-0524A	Merck	Phase 1	33
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	65
Inclisiran + Placebo	Novartis	Phase 3	77
DFV890	Novartis	Phase 2	52
Canakinumab	Novartis	Phase 2	52
Inclisiran Sodium for injection + Placebo + Placebos	Novartis	Phase 3	77
LCQ908 + Placebo	Novartis	Phase 3	77
Inclisiran	Novartis	Phase 3	77
Inclisiran + Placebo	Novartis	Phase 3	77

Other Products from Pfizer